Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis
Recruiting now
Conditions studied: Psoriatic Arthritis, Juvenile, Polyarticular Juvenile Idiopathic Arthritis
In brief
This study is to assess the safety and effectiveness of Xeljanz in Juvenile Idiopathic Arthritis (JIA) patients in routine clinical practice in Korea. JIA patients experience persistent joint pain, swelling and stiffness. This is a prospective observational study. Xeljanz is a JAK inhibitor. It was first approved in 2014 for rheumatoid arthritis patients in Korea. The ministry of Food and Drug Safety in Korea mandates for a drug manufacturer to report the post-marketing surveillance after drug's approval or indication extension. This study is to see the safety and effectiveness of Xeljanz in Juvenile Idiopathic Arthritis patients in routine clinical practice in Korea. This study is seeking patients who: * Are 2 to less than 18 years of age; * Are given Xeljanz for the treatment of JIA. The study sponsor will monitor patients' treatment experience for up to 44 weeks. This will help assess the safety and effects of this study medicine.
Key facts
- Study ID
- NCT05754710
- Run by
- Pfizer
- People needed
- 10
- Starts
- 2024-04-12
- Expected to finish
- 2026-09-30
- Last updated by the study team
- 2026-08-03
Who can join
Age: 2 and older, up to 17. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Subjects must meet all of the following inclusion criteria to be eligible for inclusion in the study:
- Pediatric subjects aged from 2 years to less than 18 years
- Xeljanz administered according to efficacy/effectiveness on the approved labeling
- Patients who will administer Xeljanz based on the medical judgement of the investigator
- Evidence of a personally signed and dated informed consent document indicating that the subject (and a legally acceptable representative) has been informed of all pertinent aspects of the study
You may not qualify if…
- Subjects meeting any of the following criteria will not be included in the study:
- Subjects who are contraindicated from taking Xeljanz according to approved labeling*
- Refer to most recently approved label
Where it is running
- Pfizer — Seoul, South Korea (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.